Abstract:
Biguanide and dihydrotriazine derivatives, preferably substituted asymmetrical imidodicarbonimidic diamides derived from hydroxylamines, and compositions containing biguanide and dihydrotriazine derivatives are disclosed. In addition, methods of using the biguanide and dihydrotriazine derivatives, inter alia, as antimicrobial agents and methods of using the dihydrotriazine derivatives in biological assays are disclosed. Methods of making the biguanide and dihydrotriazine derivatives are also disclosed.
Abstract:
An antibacterial characterized by containing as an active ingredient either a compound represented by the general formula (1) or a pharmacologically acceptable salt thereof.
Abstract:
The present invention relates to Compounds of Formula (I) and pharmaceutical compositions containing the same. It further relates to their use in the prevention or treatment of central nervous system diseases or disorders, in particular, cognitive, neurodegenerative or neuronal diseases or disorders.
Abstract translation:由通式(1)表示的化合物,其互变异构体或化合物或互变异构体的盐,其可用作杀菌剂/消毒剂。 (式中,R 1表示氢原子,可以具有取代基的烷基等,R 2表示氢原子或者可以具有取代基的烷基,或者R 1和R 2可以与相邻的氮原子结合形成任意取代的 含氮杂环基; R 4表示氢原子或任选取代的烷基; R 3表示任选取代的烷基; R 5和R 6各自表示氢原子或甲基, R 4表示氢原子,除去R1和R4表示氢原子的化合物。)
Abstract:
The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving, melting or sedimentation, in particular through sieving.
Abstract:
A new process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives for the treatment of disorders associated with insulin-resistance syndrome.
Abstract:
A compound represented by the formula (I) [wherein A represents the formula CY1Y2OCY3Y4, CY1Y2SOnCY3Y4, CY1Y2NRCY3Y4, CY1=NCY3Y4, or CY1Y2N=CY3 (wherein n is 0, 1, or 2, and Y1, Y2, Y3, and Y4 each independently represents hydrogen, alkyl, or haloalkyl); R represents hydrogen, halogeno, an optionally substituted hydrocarbon group, etc.; Q1 represents substituted phenyl or a substituted aromatic heterocyclic group; and Q2 represents substituted phenyl, alkyl, or haloalkyl] or a salt of the compound; a process for producing the compound or salt; and an insecticide containing the compound or salt. Besides being applicable by spraying, the insecticide can be used for soil treatment and seed treatment.
Abstract:
. The invention concerns compounds of general formula (I) wherein: R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. Said compounds are useful in the treatment of pathologies related to the insulin-resistance syndrome.
Abstract:
A description is given of biphenyl-substituted triazine compounds of formula (1). The biphenyl-substituted triazine compounds, which are notable for high thermal stability, are used as stabilizers for organic polymers to counter damage thereto caused by light, oxygen and heat, as light stabilizers for textile fibre materials, and as sunscreens for the human skin.